Clinical Trial 19067

Cancer Type: Thoracic
Interventions:CRS-207; Pembrolizumab (Keytruda)

Study Type: Treatment
Phase of Study: Phase II


    Study Title

    A Phase 2 Single-arm Study to Evaluate Safety and Efficacy of CRS-207 with Pembrolizumab in Adults with Previously-Treated Malignant Pleural Mesothelioma


    The purpose of this study is to evaluate whether CRS-207 with pembrolizumab is safe and effective in adults with MPM who have failed prior anti-cancer therapy.


    Assess safety and tolerability of CRS-207 and pembrolizumab. Evaluate the effect of CRS-207 and pembrolizumab on tumor response, pulmonary function, and survival. Characterize the immune response following administration of CRS-207 and pembrolizumab.

    Inclusion Criteria

  • Histologically-confirmed epithelial or biphasic MPM; biphasic tumors must have a predominantly (≥50%) epithelial component
  • No more than 2 prior lines of anti-cancer therapy, one of which must have included pemetrexed and a platinum.
  • Measurable disease as defined by modified RECIST for MPM (Byrne and Nowak, 2004)
  • Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 or 1
  • Adequate organ and marrow function
  • Adequate lung function; forced vital capacity (FVC) and forced expiratory volume in 1 second (FEV1) ≥ 45% of predicted value as measured by spirometry; and oxygen saturation ≥ 90% on room air.

  • Exclusion Criteria

  • Pleurodesis within 14 days prior to first dose of study drug
  • Receiving TNF pathway inhibitors, PI3 kinase inhibitors, systemic steroid therapy or any other form of immunosuppressive therapy within 7 days prior to the first dose of study drug
  • Active secondary malignancy
  • Prior anti-cancer monoclonal antibody within 4 weeks prior to first dose of study drug, or not recovered from adverse effects due to agents administered more than 4 weeks earlier
  • Prior chemotherapy, targeted small molecule therapy, or radiation therapy within 2 weeks prior to first dose of study drug
  • History of (non-infectious) pneumonitis that required steroids or current pneumonitis
  • Prior therapy with an anti-PD-1, anti-PD-L1, anti-PD-L2 agent, or agents targeting other checkpoint pathways (e.g. CTLA-4)
  • Prior immunotherapy with CRS-207 or any other Listeria-based agent, therapeutic cancer vaccine, or adoptive T cell immunotherapy
  • Implanted medical devices that pose high risks for colonization and cannot be easily removed (e.g., artificial heart valves, pacemakers, prosthetic joints, orthopedic screw(s), metal plate(s)) if infection occurs. Other common devices such as venous access devices (e.g., Port-a-Cath or Mediport) may be permitted as well as arterial and venous stents and dental and breast implants that were placed more than 3 months prior to first dose of study drug.